Vitamin K1 and Vitamin K2 immunopharmacological effects on the peripheral lymphocytes of healthy subjects and dialysis patients, as estimated by the lymphocyte immunosuppressant sensitivity test
Vitamin K1 and Vitamin K2 immunopharmacological effects on the peripheral lymphocytes of healthy subjects and dialysis patients, as estimated by the lymphocyte immunosuppressant sensitivity test
复制标题
DOI：
10.1111/jcpt.12747
复制
发表时间：
2018-12-01
影响因子：
2
通讯作者：
Hirano, Toshihiko
中科院分区：
文献类型：
--
作者：
Kusano, Junichi;Tanaka, Sachiko;Hirano, Toshihiko
肾移植受者接受免疫抑制治疗以预防急性排斥反应。我们评估了维生素K1（VK 1）和维生素K2（VK 2）对T细胞丝裂原激活的外周血淋巴细胞的透析患者和健康subjects.MethodsResultsThe的影响，VK 1和VK 2对T细胞丝裂原刺激的外周血单核细胞（PBMC）的增殖从12个健康人和12个透析患者进行了估计。通过BD Cytometric Beads Array试剂盒测量由活化的PBMC产生的七种细胞因子。流式细胞仪检测外周血单个核细胞（PBMC）中的调节性T细胞（TCR）为CD 4 + CD 25 + FoxP 3+淋巴细胞，VK 2剂量依赖性地抑制刀豆球蛋白A刺激的健康受试者和透析患者PBMC的增殖，而VK 1对PBMC的增殖无明显影响。VK 1和VK 2不影响这些受试者活化的PBMC产生的大多数Th 1/Th 2/Th 17细胞因子，尽管VK 2增加健康受试者PBMC产生的IL-4。低浓度VK 2治疗后，透析患者外周血单个核细胞中Treg细胞比例明显低于健康人。结论VK 2具有免疫抑制作用。VK 2可能增强糖皮质激素的免疫抑制作用，同时预防糖皮质激素引起的骨质疏松。
What is known and objectiveRenal transplant recipients receive immunosuppressive therapy to prevent acute rejection. We evaluated the immunopharmacological efficacy of vitamin K1 (VK1) and vitamin K2 (VK2) on T-cell mitogen-activated-peripheral lymphocytes of dialysis patients and healthy subjects.MethodsResultsThe effects of VK1 and VK2 on the T-cell mitogen-stimulated proliferation of peripheral blood mononuclear cells (PBMCs) obtained from 12 healthy subjects and 12 dialysis patients were estimated. Seven cytokines produced from the activated PBMCs were measured by a BD Cytometric Beads Array kit. Regulatory T cells (Tregs) in PBMCs were analysed as CD4+CD25+FoxP3+ lymphocytes by flow cytometry.VK2 dose-dependently suppressed the concanavalin A-stimulated proliferation of PBMCs from healthy subjects and dialysis patients, whereas VK1 had no significant effect on the PBMC proliferation. VK1 and VK2 did not influence the production of most of the Th1/Th2/Th17 cytokines from the activated PBMCs of these subjects, although VK2 increased the IL-4 production from PBMCs of healthy subjects. The Treg percentages in the PBMCs of dialysis patients were markedly decreased compared to healthy PBMCs after the treatment with relatively low concentrations of VK2.What is new and conclusionThe present data suggest that VK2 has immunosuppressive efficacy. VK2 may enhance the immunosuppressive efficacies of glucocorticoids while preventing osteoporosis caused by glucocorticoids.